Clinical Trial Update: Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating adding Darbe to intravenous iron to reduce transfusions while maintaining iron sufficiency in preterm infants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Deficiency
• Iron Deficiency Anemia
• Iron Malabsorption
• Premature Birth

Drugs mentioned

• Darbe (darbepoetin alfa)
• IV iron

Snippet

Sponsor: University of Washington | Conditions: Prematurity, Iron-deficiency | Phase 2 | Status: RECRUITING